Titlebook: Immunotherapy and Biomarkers in Neurodegenerative Disorders; Martin Ingelsson,Lars Lannfelt Book 2016 Springer Science+Business Media New

表示向下

Sravani Musunuri,Ganna Shevchenko,Jonas Bergquist body constituents might be terminated by immunization with a cross-reactive antigen from the environment (266]. It cannot be overemphasized how difficult it could be, at least in several in- stances, to delineate specific from non-specific events in any immunological pro- cess. Cyclic AMP may be on

責(zé)任

Immunotherapy and Biomarkers in Neurodegenerative Disorders

FEAT

強(qiáng)所

Immunotherapy Against Amyloid-β in Alzheimer’s Disease: An Overviewspecifically aimed at protofibrils of Aβ species that are thought to be most toxic have been developed and are currently being tested in phase 1 and 2 clinical trials. The first active immunotherapy with AN1792 was halted because of severe side effects. New-generation active vaccination programs wit

針葉類的樹(shù)

Immunotherapy Against N-Truncated Amyloid-β Oligomersence of high Aβ levels in brain, are acting as a waste bin, thereby keeping toxic Aβ aggregates locally fixed in a nontoxic form. Another hypothesis claims that intraneuronal Aβ aggregation triggers neuron loss and lastly many researchers believe that soluble Aβ aggregates of full-length Aβ. are the

一回合

Limousine

Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanismsying these effects is not clear. In this chapter, we review the recent active and passive immunization strategies targeting tau in mouse models and our understanding of potential mechanisms underlying the effects seen.

Mechanics

meditation

Cerebrospinal Fluid Biomarkers in Alzheimer’s Diseaseand outcome measures for clinical trials. We describe both how such analyses are currently performed in clinical chemistry laboratories and the ongoing efforts to standardise analysis between different sites. Finally, we are also providing an overview of new markers in various stages of development

鑲嵌細(xì)工

Imaging as a Diagnostic Tool in Parkinson’s Diseaseaphy (SPECT), can be used to detect dopamine deficiency, functional metabolic neuronal impairments and pathological accumulation of certain proteins in the nervous system. Similar to MRI, both PET and SPECT may also be used to aid in the differential diagnosis between Parkinson’s disease and other p